Oligovax is an emerging biopharmaceutical company focused on developing innovative therapies for cancer.

The company's lead molecule, Litenimod, is a potent agonist of Toll Like Receptor 9 (TLR9), triggering both innate and adaptive immune responses to destroy cancer cells.

Oligovax has clinical trials underway in three cancer indications and is conducting pre-clinical studies in multiple additional indications, giving a strong pipeline of potential therapeutics.